Description
Peptide YY is an endogenous neuropeptide Y-related peptide that activates Y1 and Y2 receptors. Peptide YY is an appetite-regulating hormone secreted from the gastrointestinal tract that exhibits anorexigenic activity. Peptide YY decreases osteoblast activity, contributing to bone loss in clinical settings in which patients have recently lost weight. Peptide YY also decreases levels of AMPK and phosphorylated acetyl CoA carboxylase in the liver, decreasing lipid oxidation and/or increasing lipogenesis. Peptide YY also induces slight improvements in insulin response during glucose challenge in animal models. In other in vivo models, peptide YY induces mucosal anti-secretory activity, inhibiting colonic and upper gastrointestinal transit.
References
Wong IP, Driessler F, Khor EC, et al. Peptide YY regulates bone remodeling in mice: a link between gut and skeletal biology. PLoS One. 2012;7(7):e40038. PMID: 22792209.
Shi YC, Hämmerle CM, Lee IC, et al. Adult-onset PYY overexpression in mice reduces food intake and increases lipogenic capacity. Neuropeptides. 2012 Aug;46(4):173-82. PMID: 22575886.
Tough IR, Forbes S, Tolhurst R, et al. Endogenous peptide YY and neuropeptide Y inhibit colonic ion transport, contractility and transit differentially via Y1 and Y2 receptors. Br J Pharmacol. 2011 Sep;164(2b):471-84. PMID: 21457230.
ABOUT LKT LABS
LKT Laboratories is a biochemical supply company focused on the synthesis, purification, and isolation of small molecules for research applications. Its range of products exhibit known biological activities that have found uses in a wide array of research fields, especially cancer and neuroscience. These products include protein kinase inhibitors, ion channel modulators, and activators. LKT serves the global research community by supplying the highest purity products for use in cell culture models, animal studies, or as reference materials or analytical standards.
